Tectonic Therapeutic, Inc.
TECX evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $559.3M
- Lead Asset:
- tx000045 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for TECX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TECX
Tectonic Therapeutic, Inc. (TECX) is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptors (GPCRs), with lead programs in pulmonary hypertension and heart failure.
Key risk: Pre-revenue status
BioSniper Score
Based on 4 of 6 signals
Market Cap
$559.3M
Cash Runway
—
Lead Asset
tx000045 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Tectonic Therapeutic, Inc..
Tectonic Therapeutic, Inc. (TECX) is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptors (GPCRs), with lead programs in pulmonary hypertension and heart failure.
- Clinical-stage biotech focused on GPCR-modulating biologics [sec_mda · as of 2026-02-26].
- Cash & equivalents of $227.1M as of 2026-06-30, with a cash runway of at least 12 months [sec_mda · as of 2026-08-06].
- Lead program TX45 (APEX Phase 2 trial) in PH-HFpEF/CpcPH dosed first subject in October 2024 [sec_mda · as of 2026-08-06].
- Second program TX2100 (Phase 1a healthy volunteer trial) randomized first subject in February 2026; topline results expected by end of Q3 2026 [sec_mda · as of 2026-08-06].
- Net loss of -$22.3M and shareholders' equity of $223.8M as of 2026-06-30 [sec].
What works
- Cash & equivalents of $227.1M as of 2026-06-30 provides a long cash runway, with the company stating it can fund operations for at least 12 months [sec_mda · as of 2026-08-06].
- Both lead programs (TX45 and TX2100) have achieved scheduled clinical milestones in 2026, indicating execution progress [news · published 2026-09-10].
- Competitor data (Merck CADENCE) strengthens the bull case for TX45 in CpcPH-HFpEF, suggesting a favorable class effect [news · published 2026-09-02].
What to weigh
- The company is pre-revenue with no products on the market, relying solely on cash reserves and future capital [news · published 2026-09-10].
- Net loss of -$22.3M as of 2026-06-30 reflects ongoing R&D spending without offsetting revenue [sec].
- The company warns that if it cannot raise additional capital on favorable terms, it may be forced to delay or reduce R&D programs [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash runway of at least 12 months
“We expect our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months.”
SEC MD&A · August 6, 2026
TX45 Phase 2 trial design and first subject dosed
“We dosed our first subject in the APEX Phase 2 clinical trial in October 2024.”
SEC MD&A · August 6, 2026
TX2100 Phase 1a first subject randomized and expected topline results
“In February 2026, we randomized the first subject in the Phase 1a healthy volunteer clinical trial for TX2100. As of June 2026, six single dose cohorts of healthy volunteers have been dosed. We expect to report topline results from the ongoing Phase 1a trial of TX2100 in healthy volunteers by the end of the third quarter of 2026.”
SEC MD&A · August 6, 2026
Company description as clinical-stage GPCR-focused biotech
“We are a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs.”
SEC MD&A · February 26, 2026
Catalyst timeline
- 2024-09-04 · Phase 2 start for TX45 in PH-HFpEF — A double-blind, randomized, placebo-controlled study to assess efficacy and safety of TX45 after 24 weeks in patients with pulmonary hypertension secondary to heart failure with preserved ejection fraction.
- 2026-08-01 · Phase 2 start for TX45 in pulmonary hypertension due to interstitial lung disease — An open-label study to assess the hemodynamic effect and safety of TX45 after 16 weeks in participants with pulmonary hypertension due to interstitial lung disease.
Risks & what to watch (3)›
Key risks
- Pre-revenue status — No approved products; all revenue depends on future clinical success and commercialization [news · published 2026-09-10].
- Capital dependence — If additional capital cannot be raised on favorable terms, R&D programs may be delayed or eliminated [sec_mda · as of 2026-08-06].
- Clinical trial risk — Phase 2 (TX45) and Phase 1a (TX2100) results are pending; failure would impair pipeline value [sec_mda · as of 2026-08-06].
What to watch
- Topline results from TX2100 Phase 1a trial expected by end of Q3 2026 [sec_mda · as of 2026-08-06].
- Progress of TX45 APEX Phase 2 trial in PH-HFpEF/CpcPH, with data readouts likely in 2027 [sec_mda · as of 2026-08-06].
- Ability to secure additional capital or partnerships to extend cash runway beyond 12 months [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Tectonic Therapeutic, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tectonic Therapeutic, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
111
Total value held
$411.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 2,816,494 | $87.1M |
| tcg crossover management, llc | 1,204,891 | $37.2M |
| aberdeen group plc | 1,141,824 | $35.3M |
| blackrock, inc. | 860,352 | $26.6M |
| braidwell lp | 847,151 | $26.2M |
| first light asset management, llc | 647,743 | $20.0M |
| baker bros. advisors lp | 607,788 | $18.8M |
| 5am venture management, llc | 606,660 | $18.8M |
| vanguard capital management llc | 473,532 | $14.6M |
| vestal point capital, lp | 328,000 | $10.1M |
Showing top 10 of 111 institutional holders of Tectonic Therapeutic, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 22.6%
- Days to cover
- 7.5
- Shares short
- 2,413,729
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TECX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tectonic Therapeutic, Inc.?
Tectonic Therapeutic, Inc. (TECX) is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G protein-coupled receptors (GPCRs), with lead programs in pulmonary hypertension and heart failure.
What is Tectonic Therapeutic, Inc.'s lead drug candidate?
Tectonic Therapeutic, Inc.'s most advanced tracked candidate is tx000045 (Phase 2) for Hypertension, Pulmonary.
Who is the CEO of Tectonic Therapeutic, Inc.?
Dr. Alise S. Reicin M.D., Ph.D. is the chief executive officer of Tectonic Therapeutic, Inc. (TECX).
Where is Tectonic Therapeutic, Inc. headquartered?
Tectonic Therapeutic, Inc. (TECX) is headquartered in Watertown, MA, United States.
What therapeutic areas does Tectonic Therapeutic, Inc. focus on?
Tectonic Therapeutic, Inc. develops therapies across Cardiovascular, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.